Here you can find the latest TOPADUR news & events.
TOPADUR Pharma AG announces positive results from a First-in-Human study evaluating the safety, tolerability and efficacy of TOP-N53.
TOPADUR announces the completion of Phase 1 dose escalation study of TOP-N53, a first-in-class wound healing drug candidate.
TOPADUR announces the submission of an application to the European Medicines Agency to receive Orphan Drug Designation Status.
TOPADUR in collaboration with the University Hospital of Zurich and the University of Zurich was awarded CHF 859k by Innosuisse.
TOPADUR announces positive results from an interim analysis of Phase I clinical trial with their new wound healing drug candidate.
TOP-N53: A Clinical Drug Candidate for the Treatment of Non-healing Wounds.
Do you need more information or references? Media contact
